MENU

Completed Grants and Sponsored Research

Sponsor Grant ID: 5R01HL130793-02 Project Date: September 10, 2015 - May 31, 2020
Sponsoring Organization: National Institutes Of Health (NIH)

Megakaryocyte Transcription Factor Activation to Enhance In Vitro Platelet Production from Human IPSCs

Description of Major Goals
The overall goal of this project is to investigate signaling pathways that activate megakaryocyte transcription factors as a means to enhance the efficiency of platelet production of human IPS cells.
Project Date: January 16, 2017 - January 15, 2019
Sponsoring Organization: Alex's Lemonade Stand Foundation and Babich Family Foundation

Pharmacologic Enhancement of Residual Wild Type RUNX1 Protein Activity in FPD/AML

Description of Major Goals
The goal of this project is to identify small molecules that enhance residual wild type protein in individuals with germline heterozygous RUNX1 inactivating mutations in Familial Platelet Disorder with Propensity to Develop
Sponsor Grant ID: 5K12HL087164-10 Project Date: September 1, 2012 - May 31, 2018
Sponsoring Organization: National Insititutes of Health

Clinical Hematology Research Career Development Award

Description of Major Goals
The major goal of this project is to support training in clinical research for non-malignant hematology. The long-term goal of this career development grant is to attract and retain talented young physician scientists to the field of blood diseases.
Sponsor Grant ID: 429618 Project Date: July 1, 2016 - December 31, 2017
Sponsoring Organization: St. Baldrick'S Foundation

Role of GATA2 Dysregulation in Juvenile Myelmonocytic Leukemia

Description of Major Goals
Juvenile myelomonocytic leukemia is an aggressive blood cancer of young children. The only current curative treatment is bone marrow transplantation, Yet, about 50% of children still die from their disease despite this very aggressive therapy. An improved understanding of the mechanisms that cause JMML is critical to developing new treatments. Based on recent work, we hypothesize that a protein called GATA2, which normally turns on and off white blood cell genes, is erroneously activated in JMML. This proposal is designed to test this hypothesis. Positive results would support development of medicines to inhibit GATA2 for the treatment of JMML.
Sponsor Grant ID: 5P01HL032262-34 Project Date: August 15, 2011 - April 15, 2017
Sponsoring Organization: National Heart, Lung And Blood Institute (NHLBI)

Developmental Biology of Human Erythropoiesis: Project 4

Description of Major Goals
The overall goal of this program project grant is to further understand the molecular regulation of erythroid development in humans. Dr. Cantor’s project involves elucidating the mechanisms by which GATA-1, a master erythroid transcription factor, distinguishes between direct target genes to activate versus repress and how it carries out these opposing transcriptional outputs in a gene context-dependent manner.
Sponsor Grant ID: N/A Project Date: June 9, 2014 - August 15, 2014
Sponsoring Organization: St. Baldrick'S Foundation

Role of RUNX1 (AML1) Dysregulation in Juvenile Myelomonocytic Leukemia

Description of Major Goals
This proposal aims to further elucidate the molecular pathogenesis of an aggressive cancer of young children, with the goal of identifying improved and less-toxic treatments for this disorder
Sponsor Grant ID: DP-0111-12-00 Project Date: May 15, 2012 - May 14, 2014
Sponsoring Organization: Harvard Stem Cell Institute

Runx1 Regulatory Mechanisms in Hematopoietic Stem Cell Ontogeny and Maintenance

Description of Major Goals
The main goal of this study is to further elucidate the regulatory mechanisms that govern RUNX1’s activity in hematopoietic stem cell ontogeny and maintenance. It examines interactions between RUNX1 and Bmi1, and the role of src-family kinase mediated RUNX1 tyrosine phosphorylation.
Sponsor Grant ID: N/A Project Date: February 1, 2011 - January 31, 2014
Sponsoring Organization: Gabrielle's Angel Fund For Cancer Research

Inhibition of Runx1 Tyrosine Phosphorylation in the Treatment of Human Leukemia

Description of Major Goals
The major goal of this study is to test whether clinically available src family tyrosine kinase inhibitors can block Runx1 tyrosine phosphorylation and enhance its activity.
Sponsor Grant ID: RFC Project Date: October 19, 2011 - September 18, 2012
Sponsoring Organization: Boston Children's Hospital

Role ASXL1 Mutations in Human Myelodysplastic Syndrome and Leukemia

Description of Major Goals
The aims of this study are to identify novel ASXL1 interacting proteins to further understand its function in hematopoiesis, and to test the hypothesis that mutant ASXL1 proteins associated with human leukemia have dominant negative activity.
Sponsor Grant ID: NIH RO1 HL082952 Project Date: September 30, 2005 - August 31, 2010
Sponsoring Organization: National Institutes of Health

Proteomic Approach to Further Understanding the Role of Runx-1 in Myelodysplasia

Description of Major Goals
The goals of this study were to purify and characterize Runx-1 containing multiprotein complexes in hematopoietic cells and examine the effects of myelodysplastic syndrome (MDS) associated Runx-1 mutations on observed protein-protein interactions.
Sponsor Grant ID: NIH RO1 HL075705 Project Date: January 1, 2004 - December 31, 2008
Sponsoring Organization: National Institutes of Health

Proteomic Study of Megakaryocyte Transcriptional Control

Description of Major Goals
This goal of this study is to isolate GATA-1 containing multiprotein complexes from megakaryocytes, identify the components, and assess their functional significance in megakaryopoiesis.
Project Date: July 1, 2005 - June 30, 2007
Sponsoring Organization: American Society of Hematology

Transcriptional Regulation of Megakaryopoiesis

Description of Major Goals
The main goal of this study was to further understand the transcriptional regulation of megakaryopoiesis by identifying novel GATA-1 associated proteins and assessing their functional significance in megakaryopoiesis.
Sponsor Grant ID: NCI K08 CA81275 Project Date: July 1, 1999 - June 30, 2004
Sponsoring Organization: National Institutes of Health

Role of FOG-1 in Hematopoiesis

Description of Major Goals
The major goal of this project is to define the mechanism of action of the transcriptional cofactor FOG-1 in hematopoiesis through a structure/function analysis.